Wall Street analysts expect that Mesoblast limited (NASDAQ:MESO) will post ($0.24) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Mesoblast’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Mesoblast posted earnings per share of ($0.08) in the same quarter last year, which would indicate a negative year over year growth rate of 200%. The business is expected to issue its next earnings report on Tuesday, November 13th.

On average, analysts expect that Mesoblast will report full year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.95). For the next fiscal year, analysts forecast that the company will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.09) to ($0.53). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Mesoblast.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings results on Wednesday, August 29th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Mesoblast had a negative return on equity of 10.48% and a negative net margin of 203.51%. The firm had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $2.51 million.

MESO has been the subject of several recent research reports. Maxim Group reaffirmed a “buy” rating and issued a $16.00 price target on shares of Mesoblast in a report on Friday, October 12th. HC Wainwright set a $17.00 price target on Mesoblast and gave the company a “buy” rating in a report on Tuesday, October 2nd. ValuEngine raised Mesoblast from a “hold” rating to a “buy” rating in a report on Wednesday, September 26th. Zacks Investment Research raised Mesoblast from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. Finally, Cantor Fitzgerald set a $23.00 price target on Mesoblast and gave the company a “buy” rating in a report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $14.13.

Shares of NASDAQ:MESO traded up $0.19 during midday trading on Friday, hitting $7.58. The company had a trading volume of 121,888 shares, compared to its average volume of 49,690. Mesoblast has a twelve month low of $4.74 and a twelve month high of $8.78. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.21 and a current ratio of 4.21. The stock has a market cap of $762.78 million, a PE ratio of -12.03 and a beta of 1.96.

A hedge fund recently bought a new stake in Mesoblast stock. Jane Street Group LLC purchased a new stake in Mesoblast limited (NASDAQ:MESO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,731 shares of the company’s stock, valued at approximately $102,000. Hedge funds and other institutional investors own 2.74% of the company’s stock.

About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Recommended Story: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.